Overview
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4–10), modified to eliminate hormonal activity while preserving its central nervous system effects. Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax has been extensively studied for its role in neuroprotection, cognitive enhancement, and brain-derived neurotrophic factor (BDNF) modulation. Unlike traditional stimulants, Semax does not act through direct neurotransmitter release. Instead, it influences gene expression and intracellular signalling pathways that regulate neuronal growth, adaptation, and resilience under stress conditions. Its mechanism positions it as a regulatory compound rather than an acute stimulant within cognitive research models.
What it does
Semax exerts its primary effects through upregulation of BDNF and other neurotrophins — proteins responsible for neuronal survival, synaptic plasticity, and long-term potentiation. Increased BDNF expression enhances the brain’s ability to form new neural connections, a process central to learning, memory consolidation, and adaptive cognitive function. It also modulates dopaminergic and serotonergic systems indirectly, improving signal efficiency without overstimulation. In ischemic and hypoxic research models, Semax has demonstrated neuroprotective effects by reducing oxidative stress, stabilizing neuronal membranes, and limiting excitotoxic damage. Additionally, Semax influences cerebral blood flow and metabolic activity in key brain regions, supporting improved oxygen and nutrient delivery under stress conditions. Its combined effects target both structural and functional aspects of cognitive performance.
Research areas
Neuroplasticity and synaptic adaptation · Cognitive performance and memory research · Ischemic brain injury and stroke models · Anxiety and stress-response modulation · Neuroprotection and oxidative stress research · Attention and executive function studies
Key facts
| Form | Lyophilised powder — requires reconstitution with bacteriostatic water |
| Storage | Lyophilised: -20°C. Reconstituted: 2–8°C, use within 21 days |
| Purity | ≥99% — third-party COA verified, batch-specific documentation included |
| Origin | Synthetic analogue of ACTH (4–10) fragment |
| Note | Non-hormonal derivative — no corticosteroid activity |
For research use only. Not for human consumption. This product is not approved for human use by the FDA or any regulatory body.
